

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS FO. Box 1450 Alexandria, Virginia 22313-1450 www.uspfo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/707,738	11/06/2000	Alessandro Sette	18623006250	8820	
20350	7590 07/30/2003				
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR			EXAMINER		
			VANDERVEGT, FRANCOIS P		
SAN FRANC	CISCO, CA 94111-3834		ART UNIT	PAPER NUMBER	
			1644 DATE MAILED: 07/30/2003	21	

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Tracemark Office

Address: COMMISSIONER

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR / CONTROL NO. PATENT IN REEXAMINATION			ATTORNEY DOCKET NO.		
				EXAMINER	
			ART UNIT	PAPER	
				21	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, the sequence submission filed April 15, 2002 fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Claim 78 recites the four amino acid sequence tryptophan-threonine-leucine-lysine as a core sequence of the claimed peptide, but there is SEQ ID NO: assigned to this sequence, nor is it noted to be amino acid residues xx-yy of SEQ ID NO: Z.

Applicant is reminded of the sequence rules which require a submission for all sequences of more than 9 nucleotides or 3 amino acids (see 37 CFR 1.821-1.825) and is also requested to carefully review the submitted specification for any and all sequences which require compliance with the rules.

Any inquiry concerning this communication should be directed to Examiner F. Pierre VanderVegt, Art Unit 1644, whose telephone number is (703) 305-4441. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

F. Pierre VanderVegt, Ph.D. R Art Unit 1644 Technology Center 1600

PHILLIP GAMBEL, PH.D
PRIMARY EXAMINER
7506 CONSOL 600
THEY

PTO-90C (Rev.04-03)

Application No.: 09/707 738
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

M	<ol> <li>This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
Ø	7. Other. This application contains amino acid sequences which have not been assigned a sequence identifier.
	plicant Must Provide:
Ø	An latituder substitute computer readable form (CRF) copy of the "Sequence Listing".
Ø	An <u>lattlet or</u> substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable coples are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 Patentin software help, call (703) 308-6856
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

COPY FOR (X) File [ ] Applicant

1